Federated Investors Inc. PA purchased a new stake in Reata Pharmaceuticals Inc (NASDAQ:RETA) during the 1st quarter, HoldingsChannel reports. The firm purchased 102,816 shares of the company’s stock, valued at approximately $8,788,000.

Other hedge funds have also added to or reduced their stakes in the company. UBS Oconnor LLC boosted its position in Reata Pharmaceuticals by 39.6% during the fourth quarter. UBS Oconnor LLC now owns 17,178 shares of the company’s stock worth $964,000 after acquiring an additional 4,874 shares during the last quarter. Sofinnova Investments Inc. purchased a new position in Reata Pharmaceuticals during the fourth quarter worth approximately $8,863,000. Osborn Williams & Donohoe LLC raised its stake in Reata Pharmaceuticals by 6.3% during the first quarter. Osborn Williams & Donohoe LLC now owns 77,578 shares of the company’s stock worth $6,765,000 after purchasing an additional 4,610 shares during the period. Hourglass Capital LLC purchased a new position in Reata Pharmaceuticals during the fourth quarter worth approximately $1,532,000. Finally, Rhumbline Advisers raised its stake in Reata Pharmaceuticals by 48.7% during the fourth quarter. Rhumbline Advisers now owns 24,995 shares of the company’s stock worth $1,402,000 after purchasing an additional 8,189 shares during the period. Institutional investors and hedge funds own 54.45% of the company’s stock.

In other news, insider Elaine Castellanos sold 2,000 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $85.20, for a total value of $170,400.00. Following the transaction, the insider now owns 4,138 shares of the company’s stock, valued at approximately $352,557.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Jason Douglas Wilson sold 4,000 shares of the firm’s stock in a transaction on Monday, April 15th. The shares were sold at an average price of $83.82, for a total transaction of $335,280.00. Following the completion of the transaction, the chief financial officer now directly owns 4,000 shares in the company, valued at approximately $335,280. The disclosure for this sale can be found here. In the last three months, insiders sold 21,604 shares of company stock worth $1,947,140. Insiders own 31.69% of the company’s stock.

NASDAQ:RETA opened at $88.75 on Thursday. The company has a current ratio of 5.19, a quick ratio of 5.19 and a debt-to-equity ratio of 5.23. The company has a market cap of $2.75 billion, a price-to-earnings ratio of -30.92 and a beta of 2.46. Reata Pharmaceuticals Inc has a fifty-two week low of $33.39 and a fifty-two week high of $104.53.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its earnings results on Thursday, May 9th. The company reported ($0.98) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.97) by ($0.01). The firm had revenue of $7.77 million for the quarter, compared to analyst estimates of $7.92 million. On average, equities analysts predict that Reata Pharmaceuticals Inc will post -4.61 earnings per share for the current fiscal year.

RETA has been the topic of a number of recent analyst reports. Zacks Investment Research downgraded shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, May 15th. ValuEngine raised shares of Reata Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, April 1st. Cantor Fitzgerald reaffirmed a “buy” rating and set a $100.00 price target on shares of Reata Pharmaceuticals in a research note on Thursday, February 28th. BidaskClub raised shares of Reata Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Wednesday, March 6th. Finally, Citigroup increased their price target on shares of Reata Pharmaceuticals from $185.00 to $190.00 and gave the stock a “buy” rating in a research note on Friday, May 31st. One analyst has rated the stock with a sell rating, six have issued a buy rating and one has issued a strong buy rating to the company. Reata Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $116.17.

TRADEMARK VIOLATION NOTICE: “Federated Investors Inc. PA Takes Position in Reata Pharmaceuticals Inc (NASDAQ:RETA)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://www.thecerbatgem.com/2019/06/13/federated-investors-inc-pa-takes-position-in-reata-pharmaceuticals-inc-nasdaqreta.html.

Reata Pharmaceuticals Profile

Reata Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreich's ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases.

Featured Article: Do equity income investments outperform growth and income investments?

Want to see what other hedge funds are holding RETA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reata Pharmaceuticals Inc (NASDAQ:RETA).

Institutional Ownership by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.